Small Cap Feast
Small Cap Feast – 20 September 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019
Main Market Standard
VAALCO Energy, Inc. (NYSE: EGY), an independent energy company focused on development and production assets in West Africa, today announces its formal intention to seek a Standard Listing on the Main Market of London Stock Exchange (“LSE”), to complement its existing Listing on the New York Stock Exchange.
Kaspi.kz, the largest Payments, Marketplace and Fintech Ecosystem in Kazakhstan with a leading market share in each of its key products and services, announces today the expected publication of a registration document that has been submitted for approval to the FCA and its potential intention, subject to market conditions, to undertake an initial public offering .
Main Market premium
Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators in five African growth economies. Revenue increased 7 per cent. year-on-year to US$191m (H1 2018: US$178m), with Adjusted EBITDA up 15 per cent. year-on-year at US$99m (H1 2018: US$86m) for the six months ended 30 June 2019.
Sunrise Resources (SRES) 0.14p £3.16m
Sunrise Resources provides the following positive updates on progress at its CS Pozzolan-Perlite Project in Nevada, USA.
The Company advises that good progress has been made since the last mine permitting update on 31 July when the remaining permitting steps were set out.
All of the Supplemental Environmental Reports previously in preparation have now been completed and submitted to the lead regulator, the Bureau of Land Management . The SERs analyse the impact of the CS Project on various natural resources on a cumulative basis taken with other existing or proposed developments in the project’s wider area. These impacts are considered by the Company’s environmental consultants to be minor or negligible in most cases except in respect of the mine area itself where there is a moderate but localised impact on soils and geology as would be expected for any mining operation.
Arena Events Group (ARE) 19p £30m
Arena Events Group announced that it has completed the installation of the largest single temporary hospitality structure ever installed in Japan, in partnership with Omni International in Yokohama Japan, for a rugby tournament starting this month.
The 3,800 square-meter facility, located at Shin Yokohama, adjacent to the Nissan Stadium will host guests for all seven matches at the Nissan Stadium.
This is the second time that Arena has worked at the world’s biggest rugby tournament after successful delivery in the UK in 2015. Arena was a key supplier in delivering multiple temporary structures for hospitality and back of house areas, as well as media facilities.
Sports Travel & Hospitality Japan (STHJ) was awarded the contract as sole provider of hospitality for the tournament in Japan in 2019 and will be offering a unique guest experience, combining traditional western hospitality with Japanese Omotenashi, the philosophy of Japanese hospitality. Arena has worked with STH Group on a number of high-profile sporting events.
Alien Metals Limited (UFO) 0.17p £1.89m
Alien Metals, the AIM quoted mineral exploration and development company, announced it has entered into a binding option agreement with Windfield Metals Pty Ltd to acquire a 51% interest in two exploration licences prospective for Direct Shipping Ore iron ore in the Pilbara region of Western Australia. Entering into this agreement is a significant step towards the delivery of Alien’s strategy of building a portfolio of mining projects which demonstrate development upside in global jurisdictions with an established infrastructure and mining codes, where strong operational controls can be assured.
Alien is currently exploring for silver and gold in Mexico’s richest silver mining belt, with the option agreement with Windfield allowing Alien to diversify its assets base in a tier one mining jurisdiction. The Company will continue to assess various precious and base metal projects and expand its asset base over the coming year.
Ormonde Mining PLC (ORM) 2.70p £10.40m
The Board of Ormonde provides an update on the Barruecopardo Tungsten Mine in Salamanca, Spain. The Mine, currently in the first year ramp-up operational phase, is operated by Saloro S.L.U., in which Ormonde holds a 30% beneficial interest.
Improved mined ore grades as mining in the southern starter pit transitions downwards to fresh ore and northwards towards the main orebody;
Significant progress on waste stripping of the east-wall cutback also achieved, such that initial access to the main orebody is expected early in the fourth quarter;
The Mine’s saleable concentrate inventory has been building during the initial months of operation, with Saloro preparing initial shipments of tungsten concentrates for sale within the next weeks;
To provide Saloro with additional liquidity support, as it establishes ore mining operations on the main orebody in the coming months, Saloro is in the process of finalising a €10 million, 12 month loan facility, with Oaktree Capital Management;
Eve Sleep (EVE) 3.40p £12.78m
eve Sleep, a direct to consumer sleep wellness brand operating in the UK, Ireland and France announces that the early stage merger talks with Simba Sleep Ltd, first announced on 12 August following media speculation, have ended. The board of eve has decided that now is not the right time to pursue the potential merger and that it is more appropriate to focus on the eve rebuild plan, as previously communicated to investors in the Company’s 2018 results announcement on 12 March 2019. The board will continue to seek further acquisitive growth opportunities, in addition to its focus on driving organic growth, in order to support its focus on a path to profitability.
ULS Technology (ULS) 46p £34.71m
ULS Technology, the provider of online B2B platforms for the UK conveyancing and financial intermediary markets, announces that it was informed on the afternoon of 19 September that it has been unsuccessful in re-tendering for an existing contract. The Company will continue to provide services to the customer during its notice period, and given the timing of this decision, anticipates only a relatively minor impact on its financial results for the year ended 31 March 2020. The loss of this contract is expected to have an impact of £0.4-0.5m on the Company’s profit before tax from the year ended 31 March 2021.
The trading performance of the business otherwise continues to be robust in the face of market headwinds. Both the ULS and CAL operating divisions continue to add new customers, reducing customer concentration. The Company’s Digital Move product is receiving very positive feedback and has now been used by over 1,000 consumers.
Midatech Pharma (MTPH) 5.8p £22m
Midatech Pharma, the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces it has received approval to commence a Phase 1 study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine tumours (NET). This is the next stage in the Company’s development plan for MTD201 as outlined in the Company’s announcement on 13 June 2019.
The objective of this Phase I study is to investigate subcutaneous administration as an additional injection route, compared to intramuscular administration. The study, which is being conducted in 28 healthy subjects, can now commence, with data available towards the end of 2019 or early in 2020. The objective is to determine the administration route for the pivotal registration study to be commenced in 2020.
Oncimmune (ONC) 90p £57m
Oncimmune Holdings, a leading global immunodiagnostics group, today announces that it has secured a credit facility of €8.5 million with IPF Management SA.
Under the terms of the Facility, Oncimmune will immediately draw down an initial €5 million with the remaining €3.5 million to be drawn down within six months. The Facility is for a four-year term, although it can be repaid early.
The Company intends to use the net proceeds from the Facility to drive commercial adoption of EarlyCDT® Lung, which we aim to accelerate following the recent announcement of successful results of the ECLS study at the World Conference on Lung Cancer 2019, Barcelona; bring to market other potential EarlyCDT indications as well as progressing current regulatory processes for EarlyCDT Liver. The Facility will also be used to provide business development resource for Protagen Diagnostics for which we are seeing strong demand for its services.
Ascent Resources (AST) 0.25p £7.22m
Ascent Resources, the independent oil and gas exploration and production company, operating in the Petišovci Gas Project in Slovenia, is pleased to announce that it has entered into a subscription agreement for £1,080,500 before costs, with RiverFort Global Opportunities PCC Limited, through a subscription for 393,000,000 shares at 0.275 pence per ordinary share, a premium of 10% to the closing bid price on 19 September 2019.
Gama Aviation PLC (GMAA) 75p £47.7m
Gama Aviation Plc, the global business aviation services company, today announces Daniel Ruback’s appointment to the post of Chief Financial Officer (“CFO”). Daniel’s appointment will be effective from 16th December 2019 when he will also join the Company’s Board.
Daniel is Finance Director, Signature Flight Support EMEA, a part of BBA Aviation plc, the world’s largest fixed base operation (FBO) network operator with over 200 global locations.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.